1. The outcome of low-frequency intravitreal bevacizumab therapy for macular edema in retinal vein occlusions
- Author
-
Ivanovska Adjievska B, Boskurt S, Orovcanec N, and Dimovska-Jordanova V
- Subjects
macular edema ,retinal vein occlusion ,bevacizumab ,intravitreal injection ,Ophthalmology ,RE1-994 - Abstract
Biljana Ivanovska Adjievska,1 Salih Boskurt,1 Nikola Orovcanec,2 Vesna Dimovska-Jordanova3 1Department for Posterior Segment, European Eye Hospital, Skopje, Republic of Macedonia; 2Department for Medical Statistics, Institute for Epidemiology and Medical Statistics, Medical Faculty, Skopje, Republic of Macedonia; 3Department for Retinal Diseases, University Clinic for Eyes Diseases, St Cyril and Methodius University, Skopje, Republic of Macedonia Aim: We aimed to evaluate the 1-year efficacy and safety of low-frequency intravitreal bevacizumab in the treatment of macular edema due to retinal vein occlusions (RVOs).Methods: The study comprised an interventional prospective study of patients with macular edema due to central retinal vein occlusion (CRVO) or branch retinal vein occlusion, followed for 12 months. Treatment-naïve patients with reduced best-corrected visual acuity (BCVA) and central macular thickness (CMT) of at least 250 µm received intravitreal injection of bevacizumab. After 1 month, BCVA and optical coherence tomography (OCT) images of the macula were recorded. In patients with 0.3 log of the minimum angle of resolution [logMAR] units) with average number of injections of 1.98. Improvement of mean BCVA in CRVO was significant (P=0.001) from baseline (1.2±0.95 logMAR units) to 1 year (0.75±0.6 logMAR units). Significant improvement of mean BCVA (P
- Published
- 2017